Retaining a qualified nurse workforce is a constant and costly challenge for healthcare organizations. An on-demand session for the inaugural ONS Bridge™ virtual conference reviewed strategies two institutions used to address the issue.
No matter the subspecialty, advanced practice RNs have a significant role in patient treatment and care, but little data exist about their role in radiation oncology. During a presentation at the inaugural ONS Bridge virtual conference, Lorraine Drapek, DNP, FNP-BC, AOCNP®, of Massachusetts General Hospital, and Katie Bukolt, MSN, APRN, NP-C, AOCNP®, of Baylor Charles A. Sammons Cancer Center, discussed the nuances of advanced practice in radiation therapy settings.
In February 2019, my colleagues and I published a retrospective analysis of patient-reported satisfaction comparing those who had contact with an oncology nurse navigator (ONN) and those who did not. We analyzed surveys from patients with outpatient oncology infusion or radiation oncology visits in a 24-month period. First, we sorted the surveys into two groups—self-reported ONN contact (n = 315) and self-reported no contact with an ONN (n = 172)—and compared satisfaction.
Career experts often advise individuals to develop short- and long-term goals as steps to reach their career vision. Professional development activities help support achieving those goals.
Today’s new normal has changed everything at home, from what we wear to how we teach our children—and in the oncology nursing workplace, from new precautions to the rise of telehealth. It’s also affected nurse residency programs, but one institution has thrived as it adjusted.
On September 1, 2020, the U.S. Food and Drug Administration (FDA) designated three of the situations involved in BD’s June 30, 2020, previously announced voluntary recall of several models of its Alaris™ system as class I recalls. Class I recall designation indicates a reasonable probability that the use of the product will cause serious adverse health consequences or death.
Patients with lung cancer who also had mental health disorders saw improved cancer-related outcomes when their mental illness was treated, according to findings from a study published in JAMA Oncology.
On September 1, 2020, the U.S. Food and Drug Administration (FDA) approved azacitidine tablets for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy and who are unable to complete intensive curative therapy.
In the 30 years since its inception in 1990, oncology nurse navigation has continually evolved and grown in response to patient and healthcare needs.
Since its inception in 2015, Cancer Research UK’s (CRUK) Cancer Grand Challenges initiative has led an international research effort to address the toughest barriers to progress in oncology, investing more than $130 million into seven international, multidisciplinary teams—total of 73 researcher groups in nine countries.